SpringWorks Therapeutics, Inc. (SWTX) shares plummeted 5.98% in after-hours trading on Tuesday, following reports that German pharmaceutical giant Merck KGaA is in advanced talks to acquire the U.S. cancer and rare diseases drugmaker. The potential acquisition raised concerns among analysts about the deal's profitability impact on Merck.
While the acquisition could bolster Merck's cancer-treatment pipeline, analysts questioned whether it would be accretive from the outset. Equita analyst Davide Marchesin pointed out that SpringWorks is currently loss-making despite generating over 350 million euros in annual revenue. This has led to doubts about the deal's immediate financial benefit for Merck.
The market's reaction to these profitability concerns has caused SpringWorks Therapeutics' stock to plunge in after-hours trading, reflecting investor uncertainty about the potential acquisition's implications for the company's financial performance.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。